Magainin Pharm (MAGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Magainin Pharm (MAGN)

MAGN 9.090

+6.2%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (186)	6/21/1999 2:20:00 AM
From: BulbaMan	Read Replies (1) of 233

Mike: I guess I didn't make my point clear. It's not that I expect Pfizer shareholders to buy MAGN; rather, I think the FDA should be more inclined to approve MAGN's Locilex as an anti-infective now that there's greater concern about the safety of Trovan. At $1.75, MAGN's stock price essentially reflects zero chance of Locilex's approval, so a surprise from the FDA could move the stock much higher. And it seems that Trovan's troubles have lifted Locilex's chances for approval well above zero (although they're certainly not 100%). Therefore, with little downside at its current price and lots of upside, I figure MAGN's stock is a pretty decent bet.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next